Intramedullary spinal cord abscess by *Nocardia*: A case report

Khaled Alshabani, Joseph Adrian L. Buensalido, Milagros P. Reyes, Ayman O. Soubani

**ABSTRACT**

**Introduction:** *Nocardia* is a Gram-positive bacteria that usually cause opportunistic infections but can affect the immunocompetent host. The central nervous system can be the primary site of infection in up to 40% of the cases but the involvement of the spinal cord is extremely rare. **Case Report:** We present a case of a middle age man with history of alcoholic liver cirrhosis and diabetes mellitus who presented with acute lower back pain that is associated with right leg weakness and numbness. Magnetic resonance imaging (MRI) scan showed a spinal cord intramedullary abscess. The cerebrospinal fluid analysis was consistent with meningitis and the organism was eventually identified with CSF culture as *Nocardia Farcinica*. Patient was treated with prolonged intravenous trimethoprim/sulfamethoxazole and meropenem. No neurosurgical intervention was done and the patient had full neurological recovery in few months. **Discussion:** *Nocardia* species are able to cause different kinds of disease in man. Spinal cord abscess are extremely rare and high index of clinic suspicion is required for diagnosis. Initial combination intravenous antibiotics treatment is essential and should be continued for at least three to six weeks. Treatment can be switched to oral and continued for a minimum of six months. Surgical intervention might be indicated in some patients. 16s rRNA gene sequencing allows earlier identification and thus adjustment of antibiotics. **Conclusion:** This report illustrates that a diagnosis can be made by neuroimaging and cerebrospinal fluid (CSF) 16s ribosomal RNA sequencing, allowing early and effective antibiotic therapy and obviating the need for a high-risk neurosurgical intervention.
Intramedullary spinal cord abscess by *Nocardia*: A case report

Khaled Alshabani, Joseph Adrian L. Buensalido, Milagros P. Reyes, Ayman O. Soubani

**ABSTRACT**

Introduction: *Nocardia* is a Gram-positive bacteria that usually cause opportunistic infections but can affect the immunocompetent host. The central nervous system can be the primary site of infection in up to 40% of the cases but the involvement of the spinal cord is extremely rare. Case Report: We present a case of a middle age man with history of alcoholic liver cirrhosis and diabetes mellitus who presented with acute lower back pain that is associated with right leg weakness and numbness. Magnetic resonance imaging (MRI) scan showed a spinal cord intramedullary abscess. The cerebrospinal fluid analysis was consistent with meningitis and the organism was eventually identified with CSF culture as *Nocardia Farcinica*. Patient was treated with prolonged intravenous trimethoprim/sulfamethoxazole and meropenem. No neurosurgical intervention was done and the patient had full neurological recovery in few months. Discussion: *Nocardia* species are able to cause different kinds of disease in man. Spinal cord abscess are extremely rare and high index of clinical suspicion is required for diagnosis. Initial combination intravenous antibiotics treatment is essential and should be continued for at least three to six weeks. Treatment can be switched to oral and continued for a minimum of six months. Surgical intervention might be indicated in some patients. 16s rRNA gene sequencing allows earlier identification and thus adjustment of antibiotics. Conclusion: This report illustrates that a diagnosis can be made by neuroimaging and cerebrospinal fluid (CSF) 16s ribosomal RNA sequencing, allowing early and effective antibiotic therapy and obviating the need for a high-risk neurosurgical intervention.

Keywords: Gram-positive bacteria, Intramedullary abscess, *Nocardia*, Spinal cord

How to cite this article


doi:10.5348/ijcri-201576-CR-10537

**INTRODUCTION**

*Nocardia* is known to be ubiquitous in the environment and is able to cause different kinds of diseases in man, including skin and soft tissue infections, pneumonia, central nervous system (CNS) infection and bacteremia [1]. *Nocardia* infections commonly affect immunocompromised patients and those who are on corticosteroid therapy. The lungs are usually the first organs that are infected, but the CNS eventually becomes...
infected in around 40% of cases if the primary infection is left untreated [2]. Brain abscess formation is the most common presentation of Nocardia CNS infection. Spinal cord involvement with intramedullary abscess formation is exceedingly rare. We present a rare case of such a neurological involvement as the initial presentation of Nocardia infection. We also review literature (Table 1) for this rare presentation [3–12].

CASE REPORT

A 53-year-old Caucasian male with past medical history of alcoholic liver cirrhosis, diabetes mellitus, and hypertension presented to the emergency department with acute onset lower back pain and inability to walk for two days. He also had numbness and weakness in the right leg, urinary retention and constipation. He had not had preceding respiratory or gastrointestinal illnesses or any sick contact. Physical examination was remarkable for weakness in the lower extremities that was worse on the right side, diminished pinprick and vibration sensation below the mid-thighs bilaterally, and hyporeflexia in both legs. He had mild tenderness over the lower lumbar spine.

Initial blood tests included complete blood count, basic metabolic profile, Erythrocyte sedimentation rate, and C-reactive protein were all within normal limits except for thrombocytopenia.

The patient was admitted to the general medical floor and started on intravenous (IV) dexamethasone. Computed tomography (CT) scan of the spine showed no cord compression. However, given the high clinical suspicion, a magnetic resonance imaging (MRI) showed a signal abnormality and enhancement of the spinal cord, including the conus medullaris, consistent with intramedullary abscess (Figure 1).

A lumbar puncture was performed and cerebrospinal fluid analysis (CSF) showed a red blood cell (RBC) count of 1621 RBCs/µL, nucleated cells of 4822 WBCs/µL with neutrophilic predominance (84% neutrophils), protein of 306 mg/dL, and glucose < 1 mg/dL. The Gram stain was negative. The patient was then started on broad spectrum IV antibiotics.

The initial CSF culture showed Gram-positive bacilli partially acid fast with some branching. Mycobacterium tuberculosis PCR was negative and patient was initiated on intravenous trimethoprim/sulfamethoxazole (TMP/SMX) and meropenem for Nocardia double coverage. Patient was evaluated by neurosurgery and it was decided that it was in his best interest not to intervene on the abscess as the risks outweighed the benefits. On day 10 of admission, and using 16s ribosomal RNA gene sequencing, the organism was identified as N. farcinica.

The CSF culture was finalized on day 20 of his admission and showed Nocardia farcinica, sensitive to TMP/SMX, amikacin, and imipenem, but resistant to ceftriaxone. Patient weakness started to improve slowly towards the end of his admission. He was eventually discharged to a subacute rehabilitation center on IV antibiotics. A six-month follow-up MRI scan showed resolution of the intramedullary abscess.

DISCUSSION

Nocardia is a Gram-positive bacteria of the actinomycetes group. It is responsible for nocardiosis, an uncommon infection. Nocardia species can cause localized or systemic disease usually in immunocompromised patients as an opportunistic infection, but one third of the cases occur in healthy individuals [13].

Nocardia is defined as a complex that includes N. asteroides sensu stricto, N. farcinica, N. nova, and N. transvalensis complex. Nocardia species are not part of the human flora. They are known to be ubiquitous in the environment [1]. Inhalation is the most common mode of entry and that explains the lung involvement in a majority of the infections. It can also result from trauma-related introduction of the organism [12].

Immunosuppression is a major risk factor for attracting the disease. HIV, malignancies, corticosteroid therapy, organ and hematopoietic stem cell transplantation are the most common causes of immunosuppression leading to Nocardia infections. Diabetes mellitus is a prominent risk factor. Alcoholism and COPD are important risk factors for pulmonary nocardiosis [13].

Nocardia species are able to cause different kinds of disease in man, including skin and soft tissue infections, pneumonia, CNS infection and bacteremia. The most common site of primary infection is the lung (up to
70%) [5]. CNS involvement is common in disseminated nocardiosis, but can also be the primary site [9]. CNS involvement can also occur in up to 40% of untreated primary lung lesions [2]. Brain abscess is the most common presentation of CNS nocardiosis [10]. Nocardia epidural abscesses have also been described.

Spinal cord involvement with intramedullary abscess formation is exceedingly rare and only ten cases have been reported in literature [3–12]. Our case is number 11. Yenrudi et al. reported a case of disseminated Nocardia, but we excluded it because the spinal cord involvement was secondary to thromboses of several blood vessels resulting in widespread myelomalacia and not by direct infection by the organism [14]. Of these cases, six patients were males. The mean age was 58.27 years (SD +/- 16.11). Comorbid conditions were reported in seven cases besides our patient, and included hypertension, diabetes mellitus (in four patients), end-stage renal disease, renal transplant, liver cirrhosis, chronic obstructive pulmonary disease, and ulcerative colitis. One patient was mistakenly diagnosed with allergic alveolitis, but her symptoms were secondary to the pulmonary nocardiosis as he improved dramatically with Nocardia treatment. Table 1 summarizes the main features of these cases.

Antimicrobial susceptibility patterns are variable between different studies, countries and species. Therefore, formal antimicrobial susceptibility testing is always necessary to ensure optimal therapy. There are rapid tests that can identify the organism much faster than culture and knowing the organism itself with these tests, can allow us to pattern our two empiric antibiotics by relying on studies that show the susceptibility profiles of specific species [1]. 16S ribosomal RNA gene sequencing is also a quicker method for coming up with the specific species of Nocardia, and thus allowing an earlier and improved empiric therapy while cultures are pending [15], as we did in our case.

Treatments strategies are based on cumulative retrospective experience, as well as in vitro studies, as no prospective randomized trials have been performed to determine the most effective treatment. Given the variable antibiotics resistance of Nocardia, empiric coverage with two or three agents in a patient with severe disease is warranted. TMP/SMX is a first line and standard therapy and should be included in these regimens. Combination

<table>
<thead>
<tr>
<th>Author and year reported</th>
<th>Patient’s age and gender</th>
<th>Extension of nocardiosis</th>
<th>Type of Nocardia</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kampfl [4] 1992</td>
<td>63 y/o male</td>
<td>Primary CNS: multiple cerebral and cervical spinal cord abscesses</td>
<td>N. asteroides</td>
<td>CSF consistent with bacterial meningitis + high titers of serum Nocardia IgG + complete resolution of radiological findings and partial clinical recovery with treatment</td>
<td>TMP/SMX + amikacin</td>
<td>Partial recovery 3 months after discharge</td>
</tr>
<tr>
<td>Hiller [5] 1999</td>
<td>56 y/o female</td>
<td>Disseminated: Lung + brain + single spinal cord lesion</td>
<td>N. asteroides</td>
<td>Spinal cord biopsy (consistent with abscess) + BAL. Culture positive for Nocardia</td>
<td>IV TMP/SMX</td>
<td>Partial recovery in two months</td>
</tr>
</tbody>
</table>

Table 1: Characteristics and summary of Nocardia intramedullary spinal cord abscess reported in literature
therapy is warranted in severe infections, defined as CNS involvement, disseminated disease, and infections involving more than one site in immunocompromised patients. Agents available for combination therapy include amikacin, imipenem, meropenem, third generation cephalosporins, minocycline, extended spectrum fluoroquinolones (e.g., moxifloxacin), tigecycline, and dapsone [1, 16].

Initial treatment should be administered intravenously for at least three to six weeks and/or until clinical improvement is documented. Treatment can be switched to oral and continued for a minimum of six months and up to 12 months in immunocompromised patients and those with CNS involvement.

Surgical intervention might be indicated in some situations, such as abscesses that do not respond to antibiotic therapy [12]. Prognosis is good in general, even in disseminated cases, if therapy is initiated early and continued for appropriate duration.

High index of suspicion of Nocardia infection is necessary in patients with suggestive neuroimaging. Spinal tap and stains and cultures for Nocardia are important part of the work up, but 16s rRNA allows earlier identification of the specific species, allowing adjustment of antibiotics, given the distinctly variable antibiotic susceptibilities of Nocardia species. A multidisciplinary approach that includes infectious disease, neurosurgical and neurological specialists is essential for early diagnosis and appropriate management of these patients.

### Table 1: (Continued)

<table>
<thead>
<tr>
<th>Author and year reported</th>
<th>Patient’s age and gender</th>
<th>Extension of nocardiosis</th>
<th>Type of Nocardia</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mukunda [7] 1999</td>
<td>52 y/o male</td>
<td>Primary CNS: single spinal cord lesion</td>
<td>N. asteroides</td>
<td>Laminctomy for abscess aspiration and culture</td>
<td>IV TMP/SMX + imipenem</td>
<td>Full recovery in 16 months</td>
</tr>
<tr>
<td>Durmaz [8] 2000</td>
<td>59 y/o male</td>
<td>Primary CNS: Brain and spinal cord lesions</td>
<td>N. asteroides</td>
<td>Craniotomy / laminctomy for abscess aspiration and culture</td>
<td>TMP/SMX + amikacin + ceftriaxone</td>
<td>Died on hospital day-12</td>
</tr>
<tr>
<td>Hussain [9] 2004</td>
<td>75 y/o female</td>
<td>Primary CNS: multi-loculated lesions</td>
<td>N. asteroides</td>
<td>Laminctomy for abscess aspiration and culture</td>
<td>IV TMP/SMX + cefotaxime</td>
<td>Partial recovery in 10 days</td>
</tr>
<tr>
<td>Samkoff [10] 2008</td>
<td>79 y/o male</td>
<td>Disseminated: lung + cervical spinal cord single lesion</td>
<td>N. farcinica</td>
<td>Laminctomy for abscess aspiration and culture</td>
<td>IV TMP/SMX</td>
<td>Partial recovery in 10 days but died at 8 weeks from cardiac arrest</td>
</tr>
<tr>
<td>Lee [11] 2010</td>
<td>82 y/o male</td>
<td>Primary CNS: single spinal cord lesion</td>
<td>N. cyriaciagerogica</td>
<td>Laminctomy for abscess aspiration and culture</td>
<td>IV meropenem followed by IV TMP/SMX</td>
<td>Partial recovery in 7 weeks</td>
</tr>
<tr>
<td>Hong [12] 2012</td>
<td>54 y/o female</td>
<td>Primary CNS: multiple spinal cord abscess</td>
<td>N. nova</td>
<td>Laminctomy for abscess aspiration and culture + 16s rRNA sequencing amikacin + cefotaxime + vancomycin followed by amikacin + cefotaxime</td>
<td>Full recovery in one year</td>
<td></td>
</tr>
<tr>
<td>Current report</td>
<td>53 y/o male</td>
<td>Primary CNS: meningitis + single spinal lesion</td>
<td>N. farcinica</td>
<td>CSF culture</td>
<td>IV TMP/SMX + meropenem</td>
<td>Partial recovery at 3rd weeks</td>
</tr>
</tbody>
</table>

† y/o years old
effective and resulted in significant recovery and obviated the need for a high-risk neurosurgical intervention.

**********

Author Contributions
Khaled Alshabani – Substantial contributions to conception and design, Acquisition of date, Analysis and interpretation of date, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Joseph Adrian L. Buensalido – Substantial contributions to conception and design, Analysis and interpretation of date, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Milagros P. Reyes – Substantial contributions to conception and design, Analysis and interpretation of date, Revising the article critically for important intellectual content, Final approval of the version to be published
Ayman O. Soubani – Substantial contributions to conception and design, Analysis and interpretation of date, Revising the article critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2015 Khaled Alshabani et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

EDORIUM JOURNALS

Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

**Six weeks**
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

**Four weeks**
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

**Most Favored Author program**
Join this program and publish any number of articles free of charge for one to five years.

**Favored Author program**
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

**Institutional Membership program**
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

**Our presence**
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

**Something more...**
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

We subscribe to rigorous compliance with ethical norms and standards of scholarly publishing, ensuring high quality, integrity and fairness in all our publication processes.

We request you to have a look at our website to know more about us and our services.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.